The global Wilson’s disease market is driven by the development of gene therapy as a potential cure for this disease. As per the European Association, approximately 6 to 12 percent of the total patient population suffering from liver failure is affected by Wilson’s disease, and this in turn will drive a demand for their treatment. It has also been found that females with liver failure are more prone to Wilson’s disease. In addition to this, the risk of Wilson’s disease is high among patients with low hemoglobin, jaundice, and low cholinesterase.

As patients suffering from Wilson’s Disease are unable to discharge copper at a normal rate from their liver on account of the mutation of the ATP7B gene, its treatment becomes essential. One of the key challenges of this market is the under-diagnosis of this disease. A lack of safety in the treatment offered is also another factor challenging the market. The current treatments show poor compliance and this is posing another challenge. However, the unmet need for efficient treatment for Wilson’s disease can be viewed by market players as a scope for vigorous improvement and newer discoveries can be made by doubling their efforts in research and development.

The report segments the global Wilson’s disease market on the basis of treatment, end-user, geography, and indication. By treatment, the market is segmented into penicillamine, zinc, and trientine. Of these, penicillamine continues to enjoy highest popularity as treatment option. On the basis of indication, the global Wilson’s disease market can be segmented into psychiatric, hepatic, ophthalmic, and neurological. On the basis of end-user, the market can be segmented into specialty clinics, diagnostic laboratories, and hospitals.

On the basis of geography, the market is segmented into Asia Pacific, Europe, Latin America, North America, and the Middle East and Africa. Of these, North America is leading in the Wilson’s disease market on account of growing patient awareness and increasing demand for various treatment options. Europe is anticipated to trail next. The increasing population and growing demand for quick diagnosis will boost the market in the region. The demand for improved and efficient treatment will also help the market players to strive for better discoveries and developments. The growing medical tourism in developing nations of Asia Pacific will also help the market to grow in the region.

Some of the leading players operating in the global Wilson’s disease market are Meda Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Teva Pharmaceuticals, Ipsen, Taj Pharmaceutical Limited, and Wilson Therapeutics.

Download a PDF Brochure of Report –